Ruihe Lin, MD

Pathology and Laboratory Medicine
Accepting new patients
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
View 3 additional locations
Call 800-789-7366
Headshot of Ruihe Lin, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Pathology and Laboratory Medicine

My education and training

  • Medical School: Shanghai Medical University
  • Residency: Thomas Jefferson University Hospital
  • Fellowship: University of Pennsylvania Health System
  • Fellowship: Johns Hopkins University School of Medicine

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Lin is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Zhao J, Yao J, Hosseini H, Baraban E, Lin R, Guo CC, Huo L, Lu W, Khan K, Wang S, Soto LMS, Ding Q. FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate , Histopathology, 89(2): 2026

Lin R, Gross JM, Xing D, Argani P, Lotan T, Meeker AK, Baraban EG. Alternative Lengthening of Telomeres in Malignant Perivascular Epithelioid Cell Neoplasms: Correlation With Molecular Features Including ATRX Gene Mutation Status , Modern Pathology, 39(3): 2026

Lin R, Li H, Baraban E, Lotan T, DeMarzo A, Argani P, Baras A, Matoso A. Atypical intraductal proliferation (AIP) of the prostate: Findings in repeat biopsy or radical prostatectomy in patients who met pathologic criteria for active surveillance , Human Pathology, 160: 2025

Hrizat AS, Lin R, Eberle-Singh J, O'Neill R, Xia Y, Testa JR, Uzzo R, McCue PA, Yang H, Li L. Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma. , Pathol Res Pract. , 266: 2025,155774

Lin R, Kenyon A, Wang ZX, Cai J, Iacovitti L, Kenyon LC. Pilocytic astrocytoma harboring a novel GNAI3-BRAF fusion. , Neuropathology, 43(5): 2023,391-395

Lin R, Mallick AB, Wang ZX, Brown SA, Lu B, Jiang W. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy. , Diagn Pathol., 18(1): 2023,116

Lin R, Flerova E, Wamsley CE, McCue PA, Lallas CD, Jiang W, Huang J, Wang ZX, Li L. Sarcomatoid renal cell tumor harboring a novel BYSL::TFEB fusion with concurrent TFEB amplification. , Genes Chromosomes Cancer, 62(6): 2023,353-360

Hrizat A, Lin R, Xiang Y, Holtmeyer C, Koob K, McCue PA, Yang H, Li L Tumor infiltrating T-cells and mutations of SWI/SNF genes in varying stages of ccRCC , The United States & Canadian Academy of Pathology (USCAP) Annual Meeting, New Orleans, Louisiana.: 2023

Lin R, Wang ZX, Cottrill E, Badjatia N, Gargano SM. Patient with multiple genetically distinct thyroid nodules including papillary thyroid carcinoma harboring novel YWHAG-BRAF fusion. , Cancer Genet., no volume(no issue): 2022,266-267:51-56

Lin R, Wang ZX, Kenyon L Pilocytic astrocytoma harboring a novel GNAI3-BRAF fusion , The American Association of Neuropathologists Meeting, Bonita Spring, Florida.: 2022